ReproNovo Doses First Participant in Phase 2 NORDIC Trial of RPN-002 for Embryo Implantation Support

ReproNovo Starts Phase 2 Clinical Trial in Europe

ReproNovo has announced that the first participant has been dosed in its Phase 2 clinical trial of RPN-002 in Europe. The study, called NORDIC (Nolasiban Optimized Regimen Dosing for Inhibition of Uterine Contractility), is designed to evaluate whether the investigational therapy can help improve embryo implantation during assisted reproductive technology (ART) treatments.

The company is developing RPN-002 to reduce uterine contractions and help keep the uterus in a stable state during embryo transfer. By doing this, the treatment has the potential to improve pregnancy rates and live birth rates for patients undergoing fertility treatments such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).

Trial Will Evaluate Two Different Dosing Regimens

The NORDIC study is a randomized, placebo-controlled, double-blind, parallel-group, multicenter Phase 2 clinical trial.

Researchers will evaluate two different dosing regimens of RPN-002 to understand how the treatment affects uterine contractility and endocrine parameters that may influence embryo implantation.

According to ReproNovo, this study will investigate higher doses and a longer treatment schedule than previous clinical studies. The company believes this approach could improve the chances of success for the program.

The trial plans to enroll 120 participants across five clinical sites in Europe.

Study Aims to Improve Embryo Implantation

One of the biggest challenges in assisted reproductive technology is successful embryo implantation after embryo transfer.

Even when a healthy embryo is available, implantation does not always occur. Every embryo transfer represents a significant medical, emotional, and financial commitment for patients and families.

Several research studies have shown that women with more frequent uterine contractions during embryo transfer often experience lower pregnancy rates. These contractions may interfere with the embryo's ability to implant successfully.

ReproNovo hopes that RPN-002 can help reduce these contractions and create conditions that are more favorable for embryo implantation and early pregnancy.

Company Explains the Goal of the Study

Joan-Carles Arce, MD, PhD, Chief Scientific and Medical Officer of ReproNovo, said the NORDIC study is designed to generate important pharmacodynamic data that will help identify the best dosing regimen for future clinical studies.

He explained that researchers will examine uterine contractility along with other biological factors that play a role in embryo implantation. The findings are expected to strengthen the company's understanding of how RPN-002 may support successful implantation during IVF and ICSI procedures.

Investigators Highlight the Importance of the Research

Juan A. García Velasco, MD, PhD, Chief Scientific Officer of IVIRMA and representing the investigators involved in the NORDIC study, described the first patient dosing as an important milestone.

He noted that embryo implantation remains one of the most uncertain stages of assisted reproductive technology. According to him, the data generated from the study could help guide future treatment strategies for patients undergoing fertility care.

RPN-002 Is Part of a Broader Fertility Development Program

The launch of the NORDIC study is part of ReproNovo's broader clinical development strategy focused on fertility and women's health.

The company is currently advancing several Phase 2 clinical programs worldwide, including RPN-001 for male infertility associated with low testosterone and RPN-002 for embryo implantation and adenomyosis.

ReproNovo is a clinical-stage biopharmaceutical company focused on developing new therapies that address unmet needs in male infertility, female fertility, and women's health.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!